Sign up for product news & updates
Koya Medical Launches Dayspring Lower Extremity Active Compression Treatments and CMS Issues Three New Billing Codes
Koya Medical Secures $26M in Series B Funding to Advance Portfolio of Active Compression Treatments for Lymphedema and Venous Disorders
Outcomes Rocket Podcast: Founder Discusses Treatment Gaps in Lymphedema and Koya Medical's Innovative Dayspring Treatment
Interim data presented at American Vein and Lymphatic Society Annual Congress show reduction in limb volume, improved quality of life and adherence.
FDA clears Dayspring Lite, an essential active compression treatment for lymphedema and venous disease and expands Koya's portfolio.
Space Forum Dinner discusses the implications of weightlessness in space travel on the lymphatic and venous systems and human adaptability
CMS issues new HCPCS codes for Dayspring, a novel wearable active compression treatment for lymphedema and venous diseases.
Dayspring is now FDA cleared for lymphedema and venous disease treatment in both upper and lower extremities. Koya Medical also grows leadership team.
Join CEO and President Andy Doraiswamy, Ph.D., as he provides an overview of recent business milestones and developments with Dayspring™ on May 26th.
Medical technology leader brings over 20 years of experience and a strong history of building shareholder value in the healthcare domain.
Get in touch with us to schedule a demo